BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 19022058)

  • 1. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
    Crawford Y; Ferrara N
    Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF inhibition: insights from preclinical and clinical studies.
    Crawford Y; Ferrara N
    Cell Tissue Res; 2009 Jan; 335(1):261-9. PubMed ID: 18766380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF-A: a critical regulator of blood vessel growth.
    Ferrara N
    Eur Cytokine Netw; 2009 Dec; 20(4):158-63. PubMed ID: 20167554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [VEGF, anti-vEGF and diseases].
    Corvol P
    Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.
    Bagri A; Berry L; Gunter B; Singh M; Kasman I; Damico LA; Xiang H; Schmidt M; Fuh G; Hollister B; Rosen O; Plowman GD
    Clin Cancer Res; 2010 Aug; 16(15):3887-900. PubMed ID: 20554752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of angiogenesis inhibitors in tumour treatment.
    Fayette J; Soria JC; Armand JP
    Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
    Canavese M; Altruda F; Ruzicka T; Schauber J
    J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
    Roscoe WA; Welsh ME; Carter DE; Karlik SJ
    J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
    Kong D; Okamura M; Yoshimi H; Yamori T
    Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fight against cancer: the next round.
    Doherty M
    Drug Discov Today; 2004 Nov; 9(22):947-8. PubMed ID: 15539135
    [No Abstract]   [Full Text] [Related]  

  • 17. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
    Loges S; Mazzone M; Hohensinner P; Carmeliet P
    Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic cancer therapy.
    Cao Y
    Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.
    Greenberg JI; Cheresh DA
    Expert Opin Biol Ther; 2009 Nov; 9(11):1347-56. PubMed ID: 19761418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.